S&P 500   4,519.63 (+0.74%)
DOW   35,457.31 (+0.56%)
QQQ   375.47 (+0.76%)
AAPL   148.76 (+1.51%)
MSFT   308.23 (+0.31%)
FB   339.99 (+1.39%)
GOOGL   2,864.74 (+0.32%)
TSLA   864.27 (-0.67%)
AMZN   3,444.15 (-0.08%)
NVDA   222.90 (+0.31%)
BABA   177.00 (+6.10%)
NIO   40.03 (+1.06%)
CGC   14.34 (+8.64%)
GE   104.73 (+0.59%)
AMD   116.33 (-0.09%)
MU   67.57 (+0.46%)
T   25.59 (+1.03%)
F   15.42 (-0.90%)
ACB   7.45 (+7.66%)
DIS   171.18 (+0.02%)
PFE   42.09 (+1.86%)
BA   215.97 (-0.47%)
AMC   40.80 (-5.18%)
S&P 500   4,519.63 (+0.74%)
DOW   35,457.31 (+0.56%)
QQQ   375.47 (+0.76%)
AAPL   148.76 (+1.51%)
MSFT   308.23 (+0.31%)
FB   339.99 (+1.39%)
GOOGL   2,864.74 (+0.32%)
TSLA   864.27 (-0.67%)
AMZN   3,444.15 (-0.08%)
NVDA   222.90 (+0.31%)
BABA   177.00 (+6.10%)
NIO   40.03 (+1.06%)
CGC   14.34 (+8.64%)
GE   104.73 (+0.59%)
AMD   116.33 (-0.09%)
MU   67.57 (+0.46%)
T   25.59 (+1.03%)
F   15.42 (-0.90%)
ACB   7.45 (+7.66%)
DIS   171.18 (+0.02%)
PFE   42.09 (+1.86%)
BA   215.97 (-0.47%)
AMC   40.80 (-5.18%)
S&P 500   4,519.63 (+0.74%)
DOW   35,457.31 (+0.56%)
QQQ   375.47 (+0.76%)
AAPL   148.76 (+1.51%)
MSFT   308.23 (+0.31%)
FB   339.99 (+1.39%)
GOOGL   2,864.74 (+0.32%)
TSLA   864.27 (-0.67%)
AMZN   3,444.15 (-0.08%)
NVDA   222.90 (+0.31%)
BABA   177.00 (+6.10%)
NIO   40.03 (+1.06%)
CGC   14.34 (+8.64%)
GE   104.73 (+0.59%)
AMD   116.33 (-0.09%)
MU   67.57 (+0.46%)
T   25.59 (+1.03%)
F   15.42 (-0.90%)
ACB   7.45 (+7.66%)
DIS   171.18 (+0.02%)
PFE   42.09 (+1.86%)
BA   215.97 (-0.47%)
AMC   40.80 (-5.18%)
S&P 500   4,519.63 (+0.74%)
DOW   35,457.31 (+0.56%)
QQQ   375.47 (+0.76%)
AAPL   148.76 (+1.51%)
MSFT   308.23 (+0.31%)
FB   339.99 (+1.39%)
GOOGL   2,864.74 (+0.32%)
TSLA   864.27 (-0.67%)
AMZN   3,444.15 (-0.08%)
NVDA   222.90 (+0.31%)
BABA   177.00 (+6.10%)
NIO   40.03 (+1.06%)
CGC   14.34 (+8.64%)
GE   104.73 (+0.59%)
AMD   116.33 (-0.09%)
MU   67.57 (+0.46%)
T   25.59 (+1.03%)
F   15.42 (-0.90%)
ACB   7.45 (+7.66%)
DIS   171.18 (+0.02%)
PFE   42.09 (+1.86%)
BA   215.97 (-0.47%)
AMC   40.80 (-5.18%)
NASDAQ:LYEL

Lyell Immunopharma Stock Forecast, Price & News

$13.92
+0.84 (+6.42 %)
(As of 10/19/2021 12:00 AM ET)
Add
Compare
Today's Range
$13.23
$14.26
50-Day Range
$11.00
$17.95
52-Week Range
$10.62
$19.84
Volume209,331 shs
Average Volume472,668 shs
Market Capitalization$3.33 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive LYEL News and Ratings via Email

Sign-up to receive the latest news and ratings for Lyell Immunopharma and its competitors with MarketBeat's FREE daily newsletter.


About Lyell Immunopharma

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845 for multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Headlines

Lyell Immunopharma (NASDAQ:LYEL) Shares Gap Up to $13.08
October 19, 2021 |  americanbankingnews.com
Lyell Immunopharma (NASDAQ:LYEL) Stock Price Down 4.8%
October 13, 2021 |  americanbankingnews.com
Lyell Immunopharma (NASDAQ:LYEL) Shares Gap Down to $12.94
October 11, 2021 |  americanbankingnews.com
Lyell Immunopharma (NASDAQ:LYEL) Shares Up 8%
October 7, 2021 |  americanbankingnews.com
Lyell Immunopharma (NASDAQ:LYEL) Shares Gap Down to $13.29
October 4, 2021 |  americanbankingnews.com
Lyell Immunopharma (NASDAQ:LYEL) Stock Price Down 6.8%
October 1, 2021 |  americanbankingnews.com
Lyell Immunopharma (NASDAQ:LYEL) Shares Up 7%
September 24, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LYEL
Employees
189
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$3.33 billion
Next Earnings Date
11/11/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.83 out of 5 stars

Medical Sector

764th out of 1,361 stocks

Pharmaceutical Preparations Industry

373rd out of 668 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Lyell Immunopharma (NASDAQ:LYEL) Frequently Asked Questions

Is Lyell Immunopharma a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lyell Immunopharma in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Lyell Immunopharma stock.
View analyst ratings for Lyell Immunopharma
or view top-rated stocks.

What stocks does MarketBeat like better than Lyell Immunopharma?

Wall Street analysts have given Lyell Immunopharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Lyell Immunopharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Lyell Immunopharma's next earnings date?

Lyell Immunopharma is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for Lyell Immunopharma
.

How were Lyell Immunopharma's earnings last quarter?

Lyell Immunopharma, Inc. (NASDAQ:LYEL) announced its quarterly earnings data on Thursday, August, 12th. The company reported ($1.25) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($1.54) by $0.29. The company earned $2.63 million during the quarter, compared to analyst estimates of $2.42 million.
View Lyell Immunopharma's earnings history
.

What price target have analysts set for LYEL?

4 equities research analysts have issued twelve-month target prices for Lyell Immunopharma's shares. Their forecasts range from $22.00 to $30.00. On average, they anticipate Lyell Immunopharma's share price to reach $25.50 in the next twelve months. This suggests a possible upside of 83.2% from the stock's current price.
View analysts' price targets for Lyell Immunopharma
or view top-rated stocks among Wall Street analysts.

Who are Lyell Immunopharma's key executives?

Lyell Immunopharma's management team includes the following people:
  • Dr. Richard D. Klausner, Exec. Chairman (Age 69, Pay $1.43M)
  • Ms. Elizabeth Homans, CEO & Director (Age 55, Pay $1.14M)
  • Ms. Heather D. Turner, Chief Gen. Counsel & Sec. (Age 48, Pay $917.08k)
  • Mr. Stephen J. Hill, Chief Technical Operations Officer (Age 50, Pay $722.58k)
  • Mr. Charles W. Newton, Chief Financial Officer (Age 50)
  • Nellie Dillery, Director of Accounting
  • Mr. Richard Goold Ph.D., Chief Information Officer (Age 61)
  • Ms. Lisa Ryan, Chief People Officer (Age 54)
  • Dr. Nicholas Restifo M.D., Exec. VP of Research (Age 60)
  • Ms. Elaine Cheung, Sr. VP of Corp. Strategy & Bus. Devel.

When did Lyell Immunopharma IPO?

(LYEL) raised $425 million in an initial public offering (IPO) on Thursday, June 17th 2021. The company issued 25,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, BofA Securities, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO.

What is Lyell Immunopharma's stock symbol?

Lyell Immunopharma trades on the NASDAQ under the ticker symbol "LYEL."

When does Lyell Immunopharma's lock-up period expire?

Lyell Immunopharma's lock-up period expires on Tuesday, December 14th. Lyell Immunopharma had issued 25,000,000 shares in its public offering on June 17th. The total size of the offering was $425,000,000 based on an initial share price of $17.00. After the end of Lyell Immunopharma's lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

Who are Lyell Immunopharma's major shareholders?

Lyell Immunopharma's stock is owned by a number of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (0.18%).

Which major investors are buying Lyell Immunopharma stock?

LYEL stock was acquired by a variety of institutional investors in the last quarter, including Baillie Gifford & Co..

How do I buy shares of Lyell Immunopharma?

Shares of LYEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lyell Immunopharma's stock price today?

One share of LYEL stock can currently be purchased for approximately $13.92.

How much money does Lyell Immunopharma make?

Lyell Immunopharma has a market capitalization of $3.33 billion.

How many employees does Lyell Immunopharma have?

Lyell Immunopharma employs 189 workers across the globe.

What is Lyell Immunopharma's official website?

The official website for Lyell Immunopharma is www.lyell.com.

How can I contact Lyell Immunopharma?

The company can be reached via phone at 650-695-0677.


This page was last updated on 10/19/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.